Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 7, 2020
Daily News
October 7, 2020
- Japan’s COVID-19 Vaccine, Drug Development Lack Speed: Ex-MHLW Chief Medical Officer
October 7, 2020
- Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
October 7, 2020
- Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
- NCC Verifies Utility of Genomic Analysis by Liquid Biopsy
October 7, 2020
- Keytruda Top Selling Drug in September: Encise
October 7, 2020
- Eisai, 4 Research Organizations Begin Collaborative Project for COVID-19 Treatments
October 7, 2020
- Sunovion’s Apomorphine Sublingual Hits US Market
October 7, 2020
- Chugai Licenses Antibody Engineering Tech to argenx
October 7, 2020
- MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
October 7, 2020
- Label Revisions Ordered for Takecab, 2 Other Drugs
October 7, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…